https://www.selleckchem.com/pr....oducts/8-bromo-camp.
9-12.7) in the 1991-1999 cohort, 9.3 months (95% CI, 7.6-13.2) in the 2000-2009 cohort, and 10.1 months (95% CI, 7.9-13.6) in the 2010-2019 cohort. Controlling for a number of demographic and prognostic factors, EPP (hazard ratio [HR]=0.50; 95% CI, 0.3-0.9; P=.02), pemetrexed-based chemotherapy (HR=0.59; 95% CI, 0.40-0.87; P=.007), and indwelling pleural catheters (HR=0.3; 95% CI, 0.13-0.71; P=.006) were each associated with improvements in OS. Despite the small incremental improvements in survival shown by the three interventions